Over the last few decades, Dr. Colloca has conducted studies on the behavioral, neural, and pharmacological mechanisms of pain modulation related to placebo and nocebo effects. Her lab has also developed an interest in virtual reality as a non-pharmacological approach to relieve pain and other symptoms. She has published in top-ranked international journals including Biological Psychiatry, Pain, Nature Neuroscience, JAMA, Lancet Neurology, Science and NEJM. As a result, Dr. Colloca has developed an international reputation as a leading scientist in advancing knowledge of the neurobiological mechanisms of descending pain modulation and placebo and nocebo effects with an integrative approach that includes psychopharmacological, neurobiological, and behavioral approaches.
More from Youtube
- 0:55Confronting the 4th Wave of the Drug Overdose Death Crisis | Breakthroughs Can't WaitOpioid and cocaine use epidemic is entrenched within Baltimore city, and there are no FDA-approved treatment for any stimulant disorders.At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 0:45Can a Weight-Loss Drug Help Treat Cocaine Addiction? | Breakthroughs Can’t WaitCan a weight-loss drug help treat cocaine addiction?At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters
- 4:53Changing the Future of Addiction Care | Breakthroughs Can’t Wait with Dr. Sarah KattakuzhyCan a class of drugs best known for treating diabetes and weight loss also help people struggling with cocaine use disorder?Dr. Sarah Kattakuzhy, an associate professor at the University of Maryland School of Medicine, is leading innovative research on GLP-1 receptor agonists — medications that may offer a new path forward in treating addiction.This NIH-funded research could transform how we understand and address substance use, giving people more options — and more hope.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs#BreakthroughsCantWait #AddictionResearch #CocaineUseDisorder #GLP1 #SubstanceUseDisorder #UMBResearch #NIHfunding #HealthInnovation #DrSarahKattakuzhy
- 4:24UMB's 13th Annual Interprofessional Education DayHosted by the University of Maryland Baltimore's Center for Interprofessional Education (CIPE) on April 2, IPE Day brought together more than 170 students from all seven UMB professional schools — including medicine, nursing, pharmacy, law, dentistry, physical therapy, social work, and the Graduate School — for a full afternoon of collaborative learning, simulation activities, and real-life insights into the power of team-based care.Read more: https://www.umaryland.edu/news/archived-news/april-2025/ipe-day-centers-on-listening-to-patients-and-peers.php
- 59:34Virtual Face to Face: The Challenges Facing Academic ResearchThe changes and challenges facing academic research and the University of Maryland, Baltimore's response was the topic of Virtual Face to Face on April 10 hosted by James Hughes, MBA, Chief Enterprise and Economic Development Officer and Senior Vice President. Hughes was joined by University of Maryland School of Medicine Professor and Executive Vice Dean Chris O’Donnell, PhD, and E. Albert Reece, MD, PhD, MBA, Director of the Center for Advanced Research Training and Innovation.
- 1:01:46Legal Challenges in Higher EducationOn April 1, the legal challenges facing higher education were the subjects of discussion on Virtual Face to Face. Program host and University of Maryland, Baltimore President Bruce E. Jarrell, MD, FACS, spoke with University of Maryland Francis King Carey Dean and Professor Renée; Carey Law Professor Marley Weiss, JD; and Carey Law Assistant Professor Chris Mathis, JD. The program included questions from an audience of 500 UMB faculty, staff, and students.
